Researchers from Wakayama Medical University, Hokkaido University and Noster Inc. have found that a linoleic acid-derived metabolite produced by gut microbiota can help reduce postprandial hyperglycemia in a Type 1 Diabetes (T1DM) rat model. This study sheds light on the potential of microbial metabolites to improve blood sugar control after meals.

Background on HYA and Diabetes Management

Managing blood sugar levels is crucial in Type 1 Diabetes (T1DM) to prevent complications like cardiovascular disease nerve damage and vision problems. Although insulin therapy remains the primary treatment for T1DM controlling postprandial hyperglycemia continues to pose a challenge and contributes to long-term health risks.  

Past studies have shown that fatty acids can impact glucose metabolism by influencing gut hormone activity. Linoleic acid a widely consumed dietary fat is known to activate G protein-coupled receptor 120 (GPR120) which stimulates the release of glucagon-like peptide-1 (GLP-1) a hormone that aids in blood glucose regulation. However due to its association with inflammatory effects linoleic acid’s therapeutic use is limited.HYA a lipid metabolite generated by the gut microbiome from linoleic acid has emerged as a promising alternative. It maintains the capacity to activate GPR120 and promote gut hormone secretion while avoiding the inflammatory effects associated with linoleic acid.

These findings underscore the therapeutic potential of gut microbiome-derived metabolites in the management of diabetes. Unlike conventional treatments that primarily aim to boost insulin secretion HYA demonstrates a multifaceted mode of action. It slows gastric motility enhances the release of beneficial gut hormones like GLP-1 and inhibits intestinal glucose absorption all contributing to better postprandial glucose control. Notably HYA achieves these effects without inducing inflammation positioning it as a safer and more holistic approach to glycemic regulation in T1DM.

Source: https://finance.yahoo.com/news/noster-research-gut-microbiome-derived-061400421.html